Latest rheumatoid arthritis Stories
TRONDHEIM, Norway, November 12, 2012 /PRNewswire/ -- Avexxin AS, a company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the closure of a financing B round with new and existing shareholders. Avexxin's lead project against psoriasis is expected to enter clinical trial phase I/IIa early 2013. The company also has pre-clinical development programs against rheumatoid arthritis and...
INDIANAPOLIS, Nov. 9, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology (ACR), which takes place Nov. 10-14, 2012, in Washington, D.C. These compounds include tabalumab, an anti-BAFF monoclonal antibody, and baricitinib, a janus kinase (JAK) inhibitor being developed in partnership with Incyte Corporation. The...
ATLANTA and BRUSSELS, Nov. 9, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology treatment and research, is proud to announce new data on two compounds in its immunology portfolio for a broad range of rheumatic conditions at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., November 10-14. The data include posters and oral presentations on Cimzia® (certolizumab pegol) for the treatment of moderate to...
SUMMIT, N.J., Nov. 8, 2012 /PRNewswire/ -- Protalex, Inc. (OTCBB: PRTX), a clinical stage biopharmaceutical company, today announced that it has begun screening patients at sites in the U.S. for its new multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in adults with active rheumatoid arthritis (RA). Protalex is focused on the development of a class of drugs designed to treat autoimmune and inflammatory diseases including RA. The primary objective of...
NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. The presentation will highlight new, pivotal Phase 3 study findings, including; Intravenous Golimumab Inhibits Radiographic Progression...
HAYWARD, Calif., Nov. 1, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced that an abstract of the results from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus erythematosus patients has been accepted as a late-breaking poster presentation at the 2012 Annual Scientific Meeting...
TORONTO, Oct. 31, 2012 /CNW/ - One in three respondents to the 'Fit For Work Survey' conducted for The Arthritis Society reported that they stopped working because of their arthritis. The 'Fit for Work Survey' polled 1,057 Canadians living with arthritis to investigate, identify and better understand the impact of this debilitating disease. Alarmingly, nearly 60 per cent of those individuals who stopped working because of their arthritis were between the ages of 18 and 54....
Nearly a quarter of patients with rheumatoid arthritis and osteoarthritis used complementary and alternative therapy (CAT) to help manage their condition, according to a study in the November issue of the Journal of Clinical Nursing. Researchers interviewed 250 patients aged between 20 and 90 years of age. More than two-thirds (67%) had rheumatoid arthritis and the remainder had osteoarthritis. They found that 23% used CAT in addition to prescribed drugs and that just under two-thirds...
ACR supports best practices for ultrasonography use in rheumatology More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology...
NEW YORK, Oct. 25, 2012 /PRNewswire/ -- The 12(th) annual Lupus Research Institute (LRI) Scientific Conference "Forum for Discovery" brought together more than 60 of the country's top experts in the field to focus their talent on addressing the critical questions in the autoimmune disease lupus. LRI-funded investigators presented new findings on a broad range of topics including genetic factors that predispose certain individuals to lupus, how the lupus immune system turns against...
